High plasma concentrations of acyl‐coenzyme A binding protein ( ACBP ) predispose to cardiovascular disease: Evidence for a phylogenetically conserved proaging function of ACBP
Year: 2022
Type: article
Study design: Observational Study
Abstract: Autophagy defects accelerate aging, while stimulation of autophagy decelerates aging. Acyl-coenzyme A binding protein (ACBP), which is encoded by a diazepam-binding inhibitor (DBI), acts as an extracellular feedback regulator of autophagy. As shown here, knockout of the gene coding for the yeast orthologue of ACBP/DBI (ACB1) improves chronological aging, and this effect is reversed by knockout of essential autophagy genes (ATG5, ATG7) but less so by knockout of an essential mitophagy gene (ATG32). In humans, ACBP/DBI levels independently correlate with body mass index (BMI) as well as with chronological age. In still-healthy individuals, we find that high ACBP/DBI levels correlate with future cardiovascular events (such as heart surgery, myocardial infarction, and stroke), an association that is independent of BMI and chronological age, suggesting that ACBP/DBI is indeed a biomarker of "biological" aging. Concurringly, ACBP/DBI plasma concentrations correlate with established cardiovascular risk factors (fasting glucose levels, systolic blood pressure, total free cholesterol, triglycerides), but are inversely correlated with atheroprotective high-density lipoprotein (HDL). In mice, neutralization of ACBP/DBI through a monoclonal antibody attenuates anthracycline-induced cardiotoxicity, which is a model of accelerated heart aging. In conclusion, plasma elevation of ACBP/DBI constitutes a novel biomarker of chronological aging and facets of biological aging with a prognostic value in cardiovascular disease.
Source: Aging Cell
DOI: 10.1111/acel.13751
Authors: Léa Montégut, Adrien Joseph, Hui Chen, Mahmoud Abdellatif, Christoph Ruckenstuhl, Omar Motiño, Flavia Lambertucci, Gerasimos Anagnostopoulos, Sylvie Lachkar, Silvia Dichtinger, Maria Chiara Maiuri, François Goldwasser, Benoit Blanchet, Frédéric Fumeron, Isabelle Martins, Frank Madeo, Guido Kroemer
Institutions: Inserm, Université Paris Cité, Université Paris-Saclay, Institut Gustave Roussy, Sorbonne Université, Centre de Recherche des Cordeliers, Hôpital Saint-Louis, Medical University of Graz, BioTechMed-Graz, University of Graz, Nawi Graz, Hôpital Cochin, Assistance Publique – Hôpitaux de Paris, Centre National de la Recherche Scientifique, Sorbonne Paris Cité, Université Paris Descartes, Cibles Thérapeutiques et conception de médicaments, Chimie médicinale et recherche translationnelle, Institut Necker Enfants Malades, Hôpital Européen Georges-Pompidou
Language: English
Subfield: Aging
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,509
Funders: Association pour la Recherche sur le Cancer, Mark Foundation For Cancer Research, Seerave Foundation, Equipex, European Commission, Agence Nationale de la Recherche, Fondation Leducq, Institut National de la Santé et de la Recherche Médicale, Austrian Science Fund, Fondation pour la Recherche Médicale, Ligue Contre le Cancer, China Scholarship Council, Centre National de la Recherche Scientifique, Institut Universitaire de France, Institut National Du Cancer, Medizinische Universität Graz, Bundesministerium für Bildung, Wissenschaft und Forschung, Österreichische Kardiologische Gesellschaft
Awards: Antihypertensive mechanisms of spermidine, G1413241602, Next-generation phenotypic screening for oncological applications, G2086690636, Geroprotection By Synergistic Anti-Aging Interventions, G2486910197, G2786066923, Pro-autophagic polyphenols and polyamines for longevity, Causal epigenetic changes during aging and caloric restriction, Metabolic and Autophagic Control by Acyl CoA Binding Protein (ACBP/DBI), G6329715174, Spermidine in hypertension: therapeutic potential and novel mechanisms, G7263531341, Metabolic and Cardiovascular Disease, Mechanisms of spermidine mediated neuroprotection, Université de Paris
OpenAlex ID: W4311290331
